There is increased risk for incident myocardial infarction among adults aged 18 to 64 years with joint exposure to ozone and increased ambient temperature.

The FDA has accepted the New Drug Application for ET-600, an oral solution formulation of desmopressin, for the treatment of central diabetes insipidus.

GLP-1 RAs are associated with a modestly increased risk for GERD and gallstone disease but not with GI and biliary complications.